Investor’s corner

What is ICDD’s business model ?

Well protected by its sound and comprehensive IP portfolio, ICDD-sas implements an innovative business model that

couples the provision of predictive toxicology services with the development and supply of diagnostic “efficacy marker” products, thereby addressing both major biopharmaceutical drug development hurdles. However, these activities are operated as two distinct and yet complementary businesses.

This combined “high unmet need” research and development “products and services” approach reduces both investment needs and risk, whilst the independent functioning of the two business units avoids the common interference pitfalls and reduces the likelihood of clients considering ICDD as a potential competitor.

Who to contact for more information ?

To find out more about why ICDD is such a great investment opportunity, please do not hesitate to contact Nathalie Compagnone.

What funding has been received to date ?

To date, ICDD-sas has raised 0,4 million euros. ICDD is currently seeking additional investment in order to support the further development of its two business units.